Loading…
Plus Therapeutics, Inc. is projected to rise to $7.01 by 2027, a +6% move from its current price of $6.64. PSTV is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $6.27 | $6.64 | $7.02 | -0.06% |
| May 30 | $6.12 | $6.63 | $7.18 | -0.12% |
| May 31 | $6.01 | $6.63 | $7.31 | -0.18% |
| Jun 1 | $5.92 | $6.62 | $7.41 | -0.25% |
| Jun 2 | $5.84 | $6.62 | $7.51 | -0.31% |
| Jun 3 | $5.76 | $6.62 | $7.59 | -0.37% |
| Jun 4 | $5.70 | $6.61 | $7.67 | -0.43% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.70 | $6.61 | $7.67 | -0.43% |
| Week 2 | $5.33 | $6.58 | $8.12 | -0.86% |
| Week 3 | $5.07 | $6.55 | $8.48 | -1.29% |
| Week 4 | $4.85 | $6.53 | $8.79 | -1.71% |
| Week 5 | $4.66 | $6.50 | $9.06 | -2.13% |
| Week 6 | $4.49 | $6.47 | $9.31 | -2.55% |
| Week 7 | $4.35 | $6.44 | $9.55 | -2.97% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of treatments for patients with cancer. The lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc.
and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Plus Therapeutics, Inc. (PSTV) trades at $6.59 and has a market capitalization of $45.36M. It is ranked 4638 by market cap among publicly traded entities. The current price and modest market size place PSTV in the smaller-cap healthcare space.
The long-range forecast spans 2026 through 2050, with near-term neutral expectations and later years showing bullish sentiment, including notable upside in 2033–2035 and beyond.
A major floor 56.0% below — a decisive break under it would weaken the trend.
The nearest floor, 20.9% below — buyers have tended to step in here.
The nearest ceiling, 14.8% above — a clean break opens room to run.
A major ceiling 33.6% above — clearing it would confirm fresh momentum.
Key PSTV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PSTV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.63 | Buy | $6.52 | Buy |
| MA 10 | $6.15 | Buy | $6.34 | Buy |
| MA 20 | $6.09 | Buy | $6.18 | Buy |
| MA 50 | $5.76 | Buy | $6.29 | Buy |
| MA 100 | $6.87 | Sell | $7.44 | Sell |
| MA 200 | $10.55 | Sell | $10.36 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.11 | Neutral |
| Stoch RSI (14) | 82.03 | Sell |
| CCI (20) | 117.77 | Buy |
| Williams %R (14) | -15.24 | Info |
| MACD (12,26,9) | 0.08 | Buy |
| ROC (12) | 8.50 | Buy |
| Bollinger %B (20,2) | 0.85 | Neutral |
| Stochastic %K (14) | 84.76 | Sell |
| TRIX (15) | 0.21 | Buy |
| Awesome (5,34) | 0.53 | Buy |
| Ultimate (7,14,28) | 73.19 | Sell |
| Momentum (10) | 0.79 | Buy |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 6.90 | Sell |
| ADX (14) | 11.68 | Neutral |
| ATR (14) | 0.27 | Info |
The near-term technical picture for PSTV is mixed but shows bullish momentum in the 30-day window. The RSI14 is 60, signaling room for upside before overbought conditions.
The 50-day simple moving average (SMA50) is at $5.75 and the 200-day simple moving average (SMA200) is at $10.68, framing a paper range around the current level. Support sits at $5.25 and resistance at $7.62, with a 30-day trading range from $4.45 to $9.77. Annualized volatility stands around 100, underscoring elevated price fluctuations over the period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.92 | $6.64 | $9.62 | 0% | Neutral | |
| $5.05 | $7.01 | $10.54 | +6% | Neutral | |
| $4.26 | $6.28 | $10.04 | -5% | Neutral | |
| $3.58 | $5.56 | $9.32 | -16% | Bearish | |
| $3.93 | $6.39 | $11.15 | -4% | Neutral | |
| $3.82 | $6.49 | $11.70 | -2% | Neutral | |
| $4.45 | $7.88 | $14.65 | +19% | Neutral | |
| $5.40 | $9.96 | $19.03 | +50% | Bullish | |
| $4.64 | $8.91 | $17.45 | +34% | Bullish | |
| $4.25 | $8.49 | $17.00 | +28% | Bullish | |
| $5.33 | $11.83 | $26.03 | +78% | Bullish | |
| $7.66 | $17.03 | $39.17 | +156% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.92 | $6.64 | $7.92 | +0.00% |
| June 2026 | $5.59 | $6.70 | $8.33 | +0.91% |
| July 2026 | $5.15 | $6.28 | $8.00 | -6.31% |
| August 2026 | $5.04 | $6.23 | $8.09 | -0.79% |
| September 2026 | $5.35 | $6.69 | $8.82 | +7.38% |
| October 2026 | $5.39 | $6.81 | $9.11 | +1.80% |
| November 2026 | $5.24 | $6.68 | $9.05 | -1.91% |
| December 2026 | $5.47 | $7.02 | $9.62 | +5.19% |
Click any year to see its month-by-month PSTV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The PSTV price prediction for 2026 points to an average of $6.64 (low $2.92, high $9.62) — a potential gain of 0% on today's $6.64. Price action looks broadly range-bound.
In 2027, PSTV is projected to trade between $5.05 and $10.54, averaging $7.01 — a potential gain of +6% from today's $6.64. That is up +6% on the projected 2026 average. A consolidation phase looks the most probable path here.
Plus Therapeutics, Inc.'s 2028 outlook centres on $6.28, within a $4.26 to $10.04 range. That is -10% versus the projected 2027 average. That marks a -5% change versus current levels. Price action looks broadly range-bound.
By 2029, PSTV could reach as high as $9.32, with a base case around $5.56 and support toward $3.58 — roughly -16% from $6.64. Expect choppier, lower action through this leg of the cycle.
Expect PSTV to range from $3.93 to $11.15 through 2030. The $6.39 average target implies a -4% move from current prices. That is up +15% on the projected 2029 average. Price action looks broadly range-bound.
The PSTV price prediction for 2031 points to an average of $6.49 (low $3.82, high $11.70) — a potential decline of -2% on today's $6.64. A consolidation phase looks the most probable path here.
In 2032, PSTV is projected to trade between $4.45 and $14.65, averaging $7.88 — a potential gain of +19% from today's $6.64. That is up +22% on the projected 2031 average. Price action looks broadly range-bound.
Plus Therapeutics, Inc.'s 2033 outlook centres on $9.96, within a $5.40 to $19.03 range. That is up +26% on the projected 2032 average. That marks a +50% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, PSTV could reach as high as $17.45, with a base case around $8.91 and support toward $4.64 — roughly +34% from $6.64. Momentum favours further upside here.
Expect PSTV to range from $4.25 to $17.00 through 2035. The $8.49 average target implies a +28% move from current prices. That is -5% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
The PSTV price prediction for 2040 points to an average of $11.83 (low $5.33, high $26.03) — a potential gain of +78% on today's $6.64. Momentum favours further upside here.
In 2050, PSTV is projected to trade between $7.66 and $39.17, averaging $17.03 — a potential gain of +156% from today's $6.64. That is up +44% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in PSTV today (≈ 150.60241 PSTV) could be worth
$2,564.75
+$1,564.75 (+156%) by 2050 · US Dollar
Based on the average projected PSTV price of $17.03 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PSTVwould be worth at today's price.
$1,000 invested in PSTV on May 27, 2025 (≈ 137.931034 PSTV) would be worth
$915.86
-$84.14 (-8.4%) today · 0.92× · US Dollar
Based on a PSTV entry price of $7.25 vs. today's $6.64.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.43 | $1,032.66 | +3.3% |
| 1 month ago | $5.99 | $1,108.51 | +10.9% |
| 3 months ago | $8 | $830 | -17.0% |
| 6 months ago | $15.25 | $435.41 | -56.5% |
| 1 year ago | $7.25 | $915.86 | -8.4% |
| All time (5.0y) ago | $918.75 | $7.23 | -99.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PSTV forecast.
Our base-case forecast reaches $13.00 around 2050.
Implied market cap at $13.00: $89.48M
The multi-year forecast lays out a path from a neutral near-term stance toward higher price levels in the longer run. In 2026, the avg price is $6.59 with a min of $2.92 and a max of $9.94,ROI 0, sentiment Neutral. By 2030, the avg price is expected to be $6.20 with a min of $3.81 and a max of $10.82, ROI -5.9, sentiment Neutral.
The forecast turns increasingly bullish in the mid-term and beyond. In 2033, the min is $5.10, the avg is $9.41, the max is $17.98, ROI 42.8, sentiment Bullish; likewise 2034 shows min $4.45, avg $8.55, max $16.75, ROI 29.8, sentiment Bullish; and 2035 shows min $4.10, avg $8.19, max $16.41, ROI 24.3, sentiment Bullish.
Looking farther out, 2040 posts a min of $4.88, an avg of $10.83, a max of $23.84, ROI 64.4, sentiment Bullish, and 2050 shows min $7.10, avg $15.77, max $36.27, ROI 139.3, sentiment Bullish. These figures are estimates and not guarantees. The trend suggests higher long-run potential, but each outcome depends on a range of factors and carries risk.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $6.20 with a min of $3.81 and a max of $10.82, ROI -5.9, and sentiment Neutral.
Far-term outlooks vary: 2026 shows Neutral with an avg of $6.59, while 2033–2035 and 2040–2050 show Bullish sentiment with higher avg prices and positive ROIs (2033 ROI 42.8%, 2040 ROI 64.4%, 2050 ROI 139.3%). These are estimates, not guarantees, and carry risk.
Yes, the forecast includes bullish years with max values above $20: 2033 max $17.98 falls short, but 2040 max $23.84 and 2050 max $36.27 indicate potential to exceed $20 in the longer term.
The current price is $6.59 and the market capitalization is $45.36M.
The 30-day technical picture is bullish with RSI14 at 60. SMA50 is $5.75 and SMA200 is $10.68. Support is $5.25 and resistance is $7.62, and the 30-day range is $4.45–$9.77 with annualized volatility at 100.
Plus Therapeutics, Inc. Community Discussion
0Share your Plus Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.